Validation of the Movement Disorder Society Criteria for the Diagnosis of 4‐Repeat Tauopathies

Archive ouverte

Respondek, Gesine | Grimm, Max‐joseph | Piot, Ines | Arzberger, Thomas | Compta, Yaroslau | Englund, Elisabet | Ferguson, Leslie | Gelpi, Ellen | Roeber, Sigrun | Giese, Armin | Grossman, Murray | Irwin, David | Meissner, Wassilios | Nilsson, Christer | Pantelyat, Alexander | Rajput, Alex | van Swieten, John | Troakes, Claire | Höglinger, Günter | Aiba, Ikuko | Antonini, Angelo | Barone, Paolo | Bhatia, Kailash P | Boxer, Adam K | Colosimo, Carlo | Corvol, Jean Christophe | Dickson, Dennis W | Golbe, Lawrence I | Höglinger, Günter U | Hopfner, Franziska | Irwin, David J | Josephs, Keith A | Kassubek, Jan | Kovacs, Gabor G | Lang, Anthony E | Levin, Johannes | Litvan, Irene | Höllerhage, Matthias | Mcfarland, Nikolaus | Meissner, Wassilios G | Morris, Huw R | Müller, Ulrich | Oertel, Wolfgang H | Rowe, James B | Sakakibara, Ruji | Schellenberg, Gerard | Stamelou, Maria | Eimeren, Thilo Van | Swieten, John C Van | Wenning, Gregor K | Whitwell, Jennifer L

Edité par CCSD ; Wiley -

International audience. Abstract Background The Movement Disorder Society criteria for progressive supranuclear palsy introduced the category “probable 4‐repeat (4R)‐tauopathy” for joint clinical diagnosis of progressive supranuclear palsy and corticobasal degeneration. Objectives To validate the accuracy of these clinical criteria for “probable 4R‐tauopathy” to predict underlying 4R‐tauopathy pathology. Methods Diagnostic accuracy for 4R‐tauopathies according to the established criteria was estimated retrospectively in autopsy‐confirmed patients with progressive supranuclear palsy and corticobasal degeneration (grouped as 4R‐tauopathies), and Parkinson's disease, multiple system atrophy, and frontotemporal lobar degeneration (grouped as non‐4R‐tauopathies). Results We identified 250 cases with progressive supranuclear palsy (N = 195) and corticobasal degeneration (N = 55) and with and non‐4R‐tauopathies (N = 161). Sensitivity and specificity of “probable 4R‐tauopathy” was 10% and 99% in the first year and 59% and 88% at final record. Conclusions The new diagnostic category “probable 4R‐tauopathy” showed high specificity and may be suitable for the recruitment of patients with progressive supranuclear palsy and corticobasal degeneration into therapeutic trials targeting 4R‐tauopathy. The low sensitivity underpins the need for diagnostic biomarkers. © 2019 International Parkinson and Movement Disorder Society

Consulter en ligne

Suggestions

Du même auteur

Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria

Archive ouverte | Höglinger, Günter | CCSD

International audience. Background: PSP is a neuropathologically defined disease entity. Clinical diagnostic criteria, published in 1996 by the National Institute of Neurological Disorders and Stroke/Society for PSP...

How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy

Archive ouverte | Grimm, Max-Joseph | CCSD

International audience. Background: The Movement Disorder Society criteria for progressive supranuclear palsy define diagnostic allocations, stratified by certainty levels and clinical predominance types. We aimed t...

Which ante mortem clinical features predict progressive supranuclear palsy pathology?

Archive ouverte | Respondek, Gesine | CCSD

International audience. Background: Progressive supranuclear palsy (PSP) is a neuropathologically defined disease presenting with a broad spectrum of clinical phenotypes.Objective: To identify clinical features and ...

Chargement des enrichissements...